Arrowhead Pharmaceuticals, Inc. (ARWR) stock price, news, quote and history
This article provides a comprehensive overview of Arrowhead Pharmaceuticals, Inc. (ARWR) stock, including its current price, historical data, key financial metrics, and analyst ratings. It details the company's drug pipeline with various RNAi therapeutics in different clinical trial phases. The report also highlights performance against the S&P 500 and lists revenue and earnings trends.
Long term debt to total equity ratio of Arrowhead Pharmaceuticals, Inc. – HAN:HDP1
This article focuses on the long-term debt to total equity ratio of Arrowhead Pharmaceuticals, Inc. (HDP1) on the Hannover Stock Exchange. It provides financial data related to this specific ratio, highlighting its value and change over a period. The content is presented within the context of TradingView's financial analysis tools, offering a snapshot of the company's financial health.
Free cash flow of Arrowhead Pharmaceuticals, Inc. – HAN:HDP1
The article provides financial information for Arrowhead Pharmaceuticals, Inc. (HAN:HDP1) on TradingView, specifically focusing on its free cash flow. It lists the company's stock exchange details and offers various financial and community features available on the platform for this particular stock.
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
Arrowhead Pharmaceuticals announced a webinar on October 14, 2026, to discuss investigational therapy ARO-MAPT and its CNS pipeline. The webinar will feature interim clinical data from a Phase 1/2a study of ARO-MAPT, which is an RNAi therapeutic designed to treat tauopathies like Alzheimer’s disease by silencing the MAPT gene. ARO-MAPT uses a proprietary siRNA delivery system that can cross the blood-brain barrier for systemic delivery to the CNS.
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
Arrowhead Pharmaceuticals announced it will host an R&D webinar on October 14, 2026, to present interim clinical data from its Phase 1/2a study of ARO-MAPT. This investigational RNA interference therapeutic targets tauopathies, including Alzheimer's disease, by silencing the MAPT gene. The webinar will feature presentations from Arrowhead management and Adam Boxer, M.D., Ph.D., from UCSF, discussing the ARO-MAPT program and the company's CNS pipeline.
Arrowhead Pharmaceuticals Drops 5.4% Amid Sector-Wide Selling
Arrowhead Pharmaceuticals experienced a 5.4% drop in its stock price, closing at $67.96, as a result of a widespread selloff in the biotechnology sector. Several peer companies also saw significant declines, indicating broader market concerns rather than company-specific issues for Arrowhead. Investors are advised to monitor the overall stability of the biotechnology sector rather than focusing solely on individual stock fundamentals.
Arrowhead Pharmaceuticals Plans Supplemental Drug Approval Application
Arrowhead Pharmaceuticals plans to file a supplemental application for Redemplo for severe hypertriglyceridemia by year-end, with CEO Chris Anzalone projecting peak U.S. sales of $3 billion to $4 billion. Despite an initial "slow burn" launch, sales are progressing faster than expected after insurer negotiations, and the company plans further market expansion in early 2027. Arrowhead also boasts a robust pipeline, including zodasiran for a rare high-cholesterol condition, and retail investor sentiment for ARWR stock has shifted to "extremely bullish."
ARWR Stock On Track For Worst Day In Over A Year Despite Positive Early-Stage Data For Cholesterol Drug — Retail Dismisses ‘Sell The News’ Reaction
Shares of Arrowhead Pharmaceuticals (ARWR) experienced their worst day in over a year, falling more than 10% despite releasing positive early-stage human trial data for its experimental cholesterol drug, ARO-DIMER-PA. The drug showed significant reductions in "bad" cholesterol and triglycerides, but analysts suggest the selloff could be a "sell the news" reaction, as the stock had previously run up in anticipation of the catalyst. Retail investors, however, appear to be buying the dip, with sentiment shifting from bearish to bullish on platforms like Stocktwits.
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Arrowhead Pharmaceuticals announced interim topline clinical data for ARO-DIMER-PA, its first dual-functional RNAi therapeutic for mixed hyperlipidemia, showing deep silencing of PCSK9 and APOC3 genes. The treatment led to significant reductions in PCSK9 (72%) and APOC3 (88%), as well as favorable changes in LDL-C, triglycerides, and ApoB. This clinical validation underscores Arrowhead's innovative TRiM™ platform and its potential to expand RNAi therapies for cardiometabolic diseases.
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced its participation in three investor conferences in September 2026: the Cantor Global Healthcare Conference, Morgan Stanley 24th Annual Global Healthcare Conference, and H.C. Wainwright 28th Annual Global Investment Conference. The company will deliver fireside chat presentations at each event, with presentation materials accessible on its website. Arrowhead Pharmaceuticals develops RNAi therapeutics for intractable diseases by silencing genes.
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million
A director at Arrowhead Pharmaceuticals, Michael S. Perry, sold 11,600 shares of common stock for $1 million on August 18, 2026. This sale represents 9% of his direct holdings, but he remains a significant stakeholder. Despite the sale, analysts are bullish on the stock, with a median one-year price target indicating a 26.8% gain.
Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label?
Arrowhead Pharmaceuticals (ARWR) presented Phase 3 results for plozasiran, showing a 78% reduction in pancreatitis events for severe hypertriglyceridemia patients, with a 4.1% absolute risk reduction across the broad population. While the benefit for patients with a history of pancreatitis was substantially higher (34% absolute risk reduction), the overall benefit and metabolic safety require careful consideration. The company plans to submit a supplemental New Drug Application for a broader label.
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced its participation in three investor conferences in September 2026: the Cantor Global Healthcare Conference, Morgan Stanley 24th Annual Global Healthcare Conference, and H.C. Wainwright 28th Annual Global Investment Conference. The company will conduct fireside chat presentations at each event, sharing insights into its RNAi therapeutics and pipeline for treating intractable diseases. Presentation materials will be available on the Arrowhead website.
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced its participation in three investor conferences in September 2026: the Cantor Global Healthcare Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference. The company will present in fireside chats at each event, with presentation materials available on its investor relations website. Arrowhead is a commercial-stage pharmaceutical company focused on developing RNAi therapeutics for intractable diseases.
Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split
Arrowhead Pharmaceuticals' plozasiran (Redemplo) for severe hypertriglyceridemia has received mixed reactions from analysts despite showing "placebo-like safety" in late-stage studies. While Stifel views plozasiran's safety and quarterly dosing as potential differentiators against Ionis Pharmaceuticals' monthly injectable Tryngolza, BMO Capital Markets points to concerns about plozasiran worsening glycemic control in diabetic patients. Both firms agree that the market is large enough for multiple significant products, with Arrowhead planning an FDA submission this year.
Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials
Arrowhead Pharmaceuticals announced positive 12-month results from its Phase 3 SHASTA-3 and SHASTA-4 trials for plozasiran, showing an approximate 80% reduction in triglycerides and acute pancreatitis events in severe hypertriglyceridemia patients. The company plans to seek U.S. approval for the severe hypertriglyceridemia indication before year-end, targeting a potential 2027 launch, and estimates a long-term U.S. market opportunity of $3 billion to $4 billion annually. Safety results were favorable, with high patient retention and adherence, and the company views the glycemic control observation as consistent with the broader ApoC3 inhibitor class.
Arrowhead plans regulatory filing for plozasiran in sHTG By Investing.com
Arrowhead Pharmaceuticals Inc. announced positive Phase 3 results for plozasiran in treating severe hypertriglyceridemia (sHTG), demonstrating significant triglyceride reduction and a decrease in acute pancreatitis events. The company plans to file a supplemental New Drug Application with the FDA by the end of 2026, utilizing a Priority Review Voucher. Plozasiran is already approved under the name REDEMPLO for familial chylomicronemia syndrome in several regions.
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals announced positive Phase 3 SHASTA-3 and SHASTA-4 data for plozasiran in patients with severe hypertriglyceridemia (sHTG), demonstrating significant reductions in triglycerides (79-81%) and acute pancreatitis (AP) events (78% overall, up to 100% in highest-risk group). The drug showed a favorable safety profile and the company plans to file a supplemental New Drug Application with the U.S. FDA by year-end 2026, utilizing a Priority Review Voucher. These results support plozasiran as a potentially transformative treatment for sHTG.
Have Arrowhead Pharmaceuticals Insiders Been Selling Stock?
An independent director at Arrowhead Pharmaceuticals recently sold US$1.0 million worth of stock, reducing their holding by 10%. Over the last year, the Chairman also sold US$12 million in shares at a price below the current market value. These transactions indicate a lack of insider buying over the past year, despite significant insider ownership in the company.
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
Arrowhead Pharmaceuticals will present new clinical data at the European Society of Cardiology Congress in Munich, Germany. The presentations will include detailed 12-month results from the Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in patients with severe hypertriglyceridemia, and a Phase 3 clinical trial evaluating zodasiran in Chinese adolescents and adults with homozygous familial hypercholesterolemia. The company will also host a webcast to review the ESC data.
Arrowhead Pharmaceuticals director sells $173,920 in stock
A director at Arrowhead Pharmaceuticals, Adeoye Y. Olukotun, sold 2,000 shares of company stock for $173,920. The sale occurred on August 18, 2026, when the stock was trading near its 52-week high, after a significant 322% return over the past year. Despite the stock's performance, InvestingPro analysis suggests it may be overvalued.
Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ARWR
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) reported a significant revenue increase to $829.45 million USD last year, primarily from its RNA Interference Therapeutics segment. This segment also contributed the entire $829.45 million USD from the United States market. This marks a substantial rise from the previous year's $3.55 million USD in both the segment and the US region.
Arrowhead (NASDAQ: ARWR) director to sell 2,000 shares
A director at Arrowhead Pharmaceuticals Inc. (ARWR), Adeoye Olukotun, has filed a Rule 144 notice to sell 2,000 shares of common stock through Merrill Lynch. The proposed sale, valued at $173,876.47, is expected around August 18, 2026, on NASDAQ. These shares were originally acquired as compensation from the issuer on December 18, 2025.
Arrowhead (NASDAQ: ARWR) director to sell 11,600 shares
Arrowhead Pharmaceuticals (NASDAQ: ARWR) director Michael Perry has filed a Form 144, indicating a proposed sale of 11,600 shares of common stock. The estimated aggregate market value of these shares is $1,012,171.97, and they were acquired as compensation in 2021, 2022, and 2025. The sale will be executed through Merrill Lynch on NASDAQ.
ETFs Investing in Arrowhead Pharmaceuticals, Inc. Stocks
This article lists numerous ETFs that invest in Arrowhead Pharmaceuticals, Inc. stocks, providing details such as market value, weight, issuer, management style, focus, expense ratio, AUM, price change, relative volume, and 3-year NAV total return. The ETFs cover a range of investment strategies including mid-cap, small-cap, total market, and sector-specific approaches like healthcare and biotechnology. The purpose is to make investing in these stocks more accessible and offer diversified opportunities with lower risk.
Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
Empowered Funds LLC significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 661.6% in the first quarter, adding 119,202 shares to reach a total of 137,220 shares valued at $8.6 million. This move is part of a broader trend of institutional investment, with 62.61% of the stock held by such investors. Despite missing analyst EPS estimates for the last quarter, Arrowhead Pharmaceuticals saw a 171% year-over-year revenue increase and maintains a "Moderate Buy" consensus rating from analysts with a target price of $97.33.
Avoro Capital discloses 9.64% Arrowhead Pharmaceuticals (ARWR) stake including warrants
Avoro Capital Advisors LLC and its controlling person Behzad Aghazadeh have disclosed a beneficial ownership of 9.64% in Arrowhead Pharmaceuticals (ARWR). This stake includes 13,823,383 shares of Common Stock, of which 2,467,828 shares are issuable upon the exercise of warrants. The investment firm holds sole voting and dispositive power over these shares for investment purposes on behalf of Avoro Life Sciences Fund LLC.
Why Arrowhead Pharmaceuticals (ARWR) Is Back In The Spotlight
Arrowhead Pharmaceuticals (ARWR) recently reported Q3 2026 results with sales of US$75.25 million and a net loss of US$194.28 million, attracting renewed investor attention. While the stock trades close to a common fair value estimate of $89.08, a discounted cash flow model suggests a significant long-term potential with a fair value of $174.62. The company's late-stage clinical pipeline, including plozasiran, positions it for potential growth, though risks like reliance on milestone payments remain.
Assenagon Asset Management S.A. Grows Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR
Assenagon Asset Management S.A. significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 243.8% in the second quarter, bringing its total holdings to 201,927 shares valued at $16.5 million. This move is part of a broader trend where institutional investors now own 62.61% of the company. Despite a recent downgrade by Weiss Ratings, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $97.33, following a 171% revenue increase in the latest quarter even as the company reported an adjusted loss.
How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses
Arrowhead Pharmaceuticals reported increased sales in Q3 2026, reaching US$75.25 million, but also experienced a widening net loss of US$194.28 million. Despite over US$400 million in year-to-date sales, the company's profitability is being impacted by rising expenses and reduced collaboration revenue. Investors are focusing on the commercial rollout and further approvals of REDEMPLO (plozasiran) as a potential offset to growing R&D and SG&A spending.
How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses
Arrowhead Pharmaceuticals (ARWR) reported a significant increase in Q3 2026 sales but also saw its net loss widen considerably. Despite generating over US$400 million in year-to-date sales, rising expenses and reduced collaboration revenue are impacting profitability, making the success of their late-stage programs like REDEMPLO critical for the company's financial future. Investors are now closely scrutinizing the commercial rollout and further approvals of plozasiran as a potential offset to increasing R&D and SG&A spending.
Pacer Advisors Inc. Invests $1.50 Million in Arrowhead Pharmaceuticals, Inc. $ARWR
Pacer Advisors Inc. has invested $1.50 million in Arrowhead Pharmaceuticals (NASDAQ:ARWR) by purchasing 23,922 shares in the first quarter. Institutional investors now own 62.61% of the company. Despite reporting a quarterly revenue beat, Arrowhead Pharmaceuticals missed EPS expectations, leading to some reduced future EPS forecasts by analysts, though the overall sentiment remains a "Moderate Buy" with an average price target of $97.33.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Moderate Buy" from Brokerages
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has received an average recommendation of "Moderate Buy" from thirteen brokerages, with an average 12-month price target of $97.33. Analysts have mixed outlooks, with some raising price targets and long-term EPS forecasts, while others cut near-term earnings estimates, reflecting expected losses through fiscal 2027. Despite significant revenue growth in its latest quarter, the company missed EPS expectations, reporting a larger loss than anticipated.
Arrowhead Pharmaceuticals (ARWR) Stock Retreats As Losses Deepen Behind Phase III Progress
Arrowhead Pharmaceuticals (ARWR) stock dropped 3% after reporting a widening net loss of US$194.3m in Q3 2026, despite increased revenue and positive Phase III trial results for plozasiran. The market reacted to the deepening losses, while long-term investors are likely weighing the R&D spend against the significant drug development progress. The company faces challenges with heavy cash burn and reliance on partner funding, though its late-stage pipeline is expanding.
Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $110.2, Implies 23% Upside
Arrowhead Pharmaceuticals, Inc. (ARWR) has seen its average 12-month price target raised from $107.6 to $110.2 by 10 analysts, suggesting a 23% potential upside from its August 4th closing price. The consensus rating for the stock remains a "Buy" among 14 covering analysts, with 13 recommending a Buy and one a Hold.
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
Arrowhead Pharmaceuticals has acquired an FDA Rare Pediatric Disease Priority Review Voucher to accelerate the review process for its upcoming Supplemental New Drug Application (sNDA) for plozasiran. This sNDA aims to expand the approved indication of plozasiran, currently marketed as REDEMPLO, to include patients with severe hypertriglyceridemia (sHTG). The priority review designation is expected to reduce the FDA's review time from 10 months to six months, helping to bring this important medicine to patients with sHTG more quickly.
Arrowhead Pharmaceuticals Q3 Earnings Call Highlights
Arrowhead Pharmaceuticals reported its Q3 2026 earnings, highlighting positive Phase III results for plozasiran in severe hypertriglyceridemia (SHTG) and an acceleration of its supplemental New Drug Application. The company also saw significant growth in its REDEMPLO therapy for familial chylomicronemia syndrome (FCS) and outlined upcoming pipeline readouts. Despite a net loss, revenue increased, and the company maintains a strong financial position with $1.6 billion in cash and investments.
FDA voucher could put Arrowhead's planned drug filing on a six-month review track
Arrowhead Pharmaceuticals has acquired a Rare Pediatric Disease Priority Review Voucher (PRV) from an undisclosed third party. The company plans to use this voucher to expedite the FDA review of its Supplemental New Drug Application (sNDA) for plozasiran, aimed at treating severe hypertriglyceridemia (sHTG), potentially shortening the review period to six months. This move follows positive Phase 3 clinical study results and is intended to accelerate market access for the important new medicine.
Arrowhead Pharmaceuticals Q3 Earnings Call Highlights
Arrowhead Pharmaceuticals reported positive Phase III results for plozasiran in severe hypertriglyceridemia (SHTG), leading to plans for a supplemental New Drug Application. The company also highlighted continued growth in its REDEMPLO therapy for familial chylomicronemia syndrome (FCS), with prescription volumes more than doubling. Despite a net loss of $194.3 million in Q3, revenue increased significantly due to collaboration agreements and REDEMPLO sales, and the company maintains a strong financial position with $1.6 billion in cash and investments.
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
Arrowhead Pharmaceuticals announced its fiscal 2026 third-quarter results, highlighting significant progress in its commercial product REDEMPLO and its robust R&D pipeline. Key achievements include the strong momentum of REDEMPLO's U.S. launch and new marketing authorizations in Europe and Australia, positive topline results for plozasiran in severe hypertriglyceridemia, and advancements in other clinical programs. The company also acquired a priority review voucher for plozasiran and entered into a significant licensing agreement for ARO-PNPLA3.
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced it has acquired a Rare Pediatric Disease Priority Review Voucher (PRV) from an undisclosed third party. The company plans to use this PRV to accelerate the review of its Supplemental New Drug Application (sNDA) for plozasiran, aimed at expanding its approved indication to include patients with severe hypertriglyceridemia (sHTG). This acquisition could shorten the FDA review process for plozasiran from 10 to six months, highlighting its potential to transform treatment for sHTG patients.
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - August 3, 2026
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced that its Board of Directors approved inducement grants for 95 new employees on July 16, 2026. These grants, totaling up to 112,794 restricted stock units, fall under NASDAQ Listing Rule 5635(c)(4) and are separate from stockholder-approved equity incentive plans, vesting annually over four years. Arrowhead Pharmaceuticals is a commercial-stage pharmaceutical company focused on developing RNAi therapeutics to treat intractable diseases.
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Arrowhead Pharmaceuticals, Inc. announced that its Board of Directors approved inducement grants to 95 new employees on July 16, 2026. These grants, totaling up to 112,794 restricted stock units, are made under NASDAQ Listing Rule 5635(c)(4) and vest annually over four years, operating outside the company's existing equity incentive plans. The company specializes in developing RNAi therapeutics for various intractable diseases.
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Plozasiran’s Phase 3 Success And Zodasiran Milestone
Arrowhead Pharmaceuticals announced positive Phase 3 results for plozasiran in severe hypertriglyceridemia and completed enrollment for the zodasiran Phase 3 trial. These developments bolster the company's cardiometabolic RNAi pipeline, potentially diversifying future revenue and broadening treatment options for lipid disorders. The strong clinical data may positively impact Arrowhead's investment narrative and risk profile, especially as earlier analyst estimates were more pessimistic.
Vanguard unit discloses 6.38M Arrowhead (ARWR) shares, a 4.53% stake
Vanguard Portfolio Management LLC, along with its affiliates, has reported a beneficial ownership of 6,384,903 shares in Arrowhead Pharmaceuticals Inc. (ARWR), representing a 4.53% stake in the company. This disclosure, filed as a SCHEDULE 13G/A, indicates that Vanguard Portfolio Management has sole voting power over 33,548 shares and sole dispositive power over all 6.38 million shares. The filing clarifies that no single individual investor within Vanguard's managed accounts holds more than 5% of Arrowhead's common stock.
B. Riley Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $123
B. Riley Securities has reiterated its Buy rating for Arrowhead Pharmaceuticals (ARWR.US) and increased the price target to $123. This adjustment reflects the firm's continued confidence in the company's financial prospects and market position.
Arrowhead Pharmaceuticals (ARWR) Could Be 3% Undervalued On Late Stage Trial Progress
Arrowhead Pharmaceuticals (ARWR) appears to be 3% undervalued, according to a recent analysis, following positive late-stage trial data for two RNA interference programs. The company's stock has seen significant momentum, with a 7x return over the past year, driven by reassessments of its risk and opportunity mix. While a discounted cash flow model suggests the stock is heavily undervalued, the narrative relies on revenue growth, margin expansion, and successful trial progression, making it sensitive to potential setbacks.
Arrowhead Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data
Arrowhead Pharmaceuticals (ARWR) had 801 employees worldwide as of March 2026, marking a 51.4% growth since 2023. The company is actively hiring, with 152 active job postings in 2026, and its workforce is primarily concentrated in the United States. Revelio Labs data indicates that the average salary is $135,729 and employee sentiment is neutral but improving.
Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $105.4, Implies 23% Upside
Arrowhead Pharmaceuticals, Inc.'s stock 12-month price target has been increased from $104.7 to $105.4 by analysts, indicating a potential 23% upside from its July 27th closing price. The consensus rating from 14 analysts remains a "Buy," with a range of forecasts from $87 to $126 per share.
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
Arrowhead Pharmaceuticals has completed enrollment in its global Phase 3 YOSEMITE clinical trial for zodasiran, an investigational RNAi therapeutic targeting homozygous familial hypercholesterolemia (HoFH). The study, which enrolled 70 patients, is expected to be completed in mid-2027, after which Arrowhead plans to seek regulatory approval. Zodasiran works by reducing ANGPTL3 expression to lower atherogenic lipoproteins, offering a new treatment approach for this rare genetic condition that causes severely elevated LDL-C and early-onset cardiovascular disease.
